Evidence supporting the use of: Creatine Malate
For the health condition: Parkinson's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Creatine, most commonly in the form of creatine monohydrate, has been studied as a potential neuroprotective agent in Parkinson’s Disease (PD). The rationale is based on creatine’s role in cellular energy metabolism: it helps buffer cellular ATP levels, potentially protecting neurons from energy failure, which is a feature of neurodegenerative diseases such as PD. Some preclinical studies (animal models and cell cultures) have shown that creatine supplementation can reduce dopaminergic neuron loss and improve motor function in PD models. Early-phase human clinical trials suggested possible modest benefits regarding slowed disease progression or improved motor function. However, a large, multicenter phase III clinical trial (the NET-PD LS-1 study, published in 2015) found no evidence that creatine significantly slowed clinical decline in people with early PD over five years.

Regarding creatine malate specifically, there is very limited scientific data addressing its use in Parkinson’s Disease, as most studies have used creatine monohydrate. The theoretical benefits would be similar due to the shared creatine component, but no robust clinical trials have examined creatine malate in this context. In summary, while there is a scientific rationale and some early evidence supporting creatine’s use in PD, high-quality clinical trials have not demonstrated a clear benefit, and there is little to no direct evidence for creatine malate itself in PD.

More about Creatine Malate
More about Parkinson's Disease

Products containing Creatine Malate

We currently have no products on Vitabase that contain this ingredient.